Cameron Turtle, Chief Business Officer at Eidos Therapeutics, Inc. (EIDX), sold 44,988 shares at $112.97 ($5.0M) on 2020-12-15, disclosed to the SEC on 2020-12-16.
Open-market sale of $5.0M EIDX by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $110.29 | 3,756 | $414K | 8.2% |
| 2 | $110.29 | 3,756 | $414K | 8.2% |
| 3 | $111.31 | 7,600 | $846K | 16.8% |
| 4 | $112.19 | 11,445 | $1.3M | 25.5% |
| 5 | $112.19 | 11,445 | $1.3M | 25.5% |
| 6 | $112.97 | 3,493 |
| $395K |
| 7.8% |
| 7 | $112.97 | 3,493 | $395K | 7.8% |
| Total | $111.85 avg | 44,988 | $5.0M | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |